Evaluation of two European risk models for predicting medication harm in an Australian patient cohort
- 18 January 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 78 (4), 679-686
- https://doi.org/10.1007/s00228-021-03271-1
Abstract
Purpose To externally evaluate the performance of two European risk prediction models, for identifying patients at high-risk of medication harm, in an Australian hospital setting. Methods This was a secondary analysis of a pre-existing cohort study described in a recently published study by Falconer et al. (Br J Clin Pharmacol 87(3):1512–1524, 2021) describing the development of a predictive risk model for inpatient medication harm. We retrospectively extracted relevant variables using the electronic health records of general medical and geriatric patients admitted to a quaternary hospital, in Brisbane, over 6 months from July to December 2017. This dataset was used to externally evaluate the two European models, The Brighton Adverse Drug Reaction Risk (BADRI) model by Tangiisuran et al. and a risk model developed by Trivalle et al. The variables were entered into both models and the patients’ risk of medication harm was calculated, and compared with actual patient outcomes. Predictive performance was evaluated by measuring area under the receiver operative characteristic (AuROC) curves. Results The Australian patient cohort included 1982 patients (median age 74 years), of which 136 (7%) patients experienced ≥ 1 medication harm event(s). External evaluation of the two European models identified that both the BADRI and the Trivalle models had reduced predictive performance in an Australian patient cohort, compared with their original studies (AuROC of 0.63 [95% CI: 0.58–0.68] and 0.60 [95% CI: 0.55–0.65], respectively). Conclusion Neither model demonstrated sufficient discrimination to warrant further evaluation in our local setting. This is likely a result of variations between the development and the validation cohorts, and the change in healthcare systems over time, and highlights the need for an up-to-date and context-specific risk prediction model.Keywords
Funding Information
- The University of Queensland (PhD Scholarship (RTP))
This publication has 29 references indexed in Scilit:
- Risk prediction models: II. External validation, model updating, and impact assessmentHeart, 2012
- Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)markerHeart, 2012
- Risk factors for adverse drug events in hospitalized elderly patients: A geriatric scoreEuropean Geriatric Medicine, 2011
- Development and Validation of a Score to Assess Risk of Adverse Drug Reactions Among In-Hospital Patients 65 Years or OlderJAMA Internal Medicine, 2010
- Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-EpisodesPLOS ONE, 2009
- The Effect of Electronic Prescribing on Medication Errors and Adverse Drug Events: A Systematic ReviewJournal of the American Medical Informatics Association, 2008
- Adverse drug event trigger tool: a practical methodology for measuring medication related harmPublished by BMJ ,2003
- Preventable and Non-Preventable Risk Factors for Adverse Drug Events Related to Hospital Admissions in the ElderlyClinical Drug Investigation, 2002
- Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study GroupJAMA, 1995
- Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of preventionJournal of Internal Medicine, 1990